Good morning, ladies and gentlemen, and welcome to the Cooper-Standard Third Quarter 2025 Earnings Conference Call. As a reminder, this conference call is being recorded, and the webcast will be ...
Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of four posters in patients with hepatorenal syndrome (HRS), including a Poster of Distinction, at The ...
Dose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks feedback from multiple regulatory agencies Enhanced clinical leadership ...
John Shegerian, Chairman and CEO of ERI, the nation's leading material resource recovery, ITAD, mobility and data destruction/processing provider, last week delivered guest lectures to three ...
The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG ...
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically ...
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company’s registrational KYSA-6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback